Search results for " titer"
Article
Fusion Proteins Pose Manufacturability Challenges
The titers for fusion proteins are generally lower than those for mAbs due to less efficient translation, notes Chamow.
Non-human glycans—such as N-glycolylneuraminic acid and alpha-galactose—are …
Article
Evolution of the Monoclonal Antibody Purification Platform
Some process development related attributes with respect to production of mAbs include:
• Significant increase in titer levels over the past decade (from 0.5 mg/mL to 5-10 mg/mL)
• High pr…
Article
Digitalization: The Route to Biopharma 4.0
The strategy was designed to handle deviations in titer from 1 g/L to 7 g/L by selecting a pre-programmed set of methodologies designed as per the requirements. In another study, integrated process mo…
Article
Simple Fed-Batch Process Development for a Knockout Cell Line
CLICK HERE TO READ MORE >>
This workflow improved titers by 500% compared with Chinese hamster ovary cell culture in basal medium.
Article
Updating Viral Clearance for New Biologic Modalities
“If viruses are similar in size to the pore size of the VRF membrane, the extent to which a filter can reduce virus titer depends on the flow conditions applied to the VRF. Interrupting flow can exace…
Article
Improving mAb Manufacturing Productivity by Optimizing Buffer and Media Prep Process Flow
A typical monoclonal antibody (mAb) process may require 2000 L of a buffer and more than 100,000 L per batch based on titer and bioreactor volume (1, 2). As a result, the variety of buffer solutions u…
Article
Improving Upstream Predictability
“We’ve consistently been seeing titers in the range of 4–6 g/L in [monoclonal antibody] mAb fed-batch processing within a chemically defined media environment. This environment, in turn, results in mo…
Article
Maximizing the Effectiveness of Upstream Bioprocessing Through the Combination of Lab Informatics and Instrumentation
Novel techniques including Raman spectroscopy and other advanced monitoring methods have the potential to reduce the reliance on discrete sampling points for off-line analytics such as titer measureme…
Article
Mapping a Route for Cell and Gene Therapy Process Development
The productivity largely depends on the harvest titer and downstream process yield. Moreover, the product design at the molecular level, the producer cell line, and the production medium can all be li…
Article
Best Practices for Selecting a Top-Quality Cell Line
Defining high-quality cell lines
A high-quality cell line will demonstrate high stability, scalability, and high titer, so that it can provide reproducible results—with all product quality attribu…